Direct comparison
GLP vs GMP: Key Differences
GLP governs nonclinical safety studies (21 CFR 58); GMP governs drug manufacturing (21 CFR 210/211, ICH Q7). Compare scope, rules, and consequences.
Side-by-side comparison
| Dimension | GLP | GMP |
|---|---|---|
| Full name | Good Laboratory Practice | Good Manufacturing Practice |
| What it governs | Conduct of nonclinical (in vitro / animal) safety and toxicology studies | Manufacturing, testing, and release of a drug substance/product, including investigational product (IMP) used in trials |
| Primary US regulation | 21 CFR Part 58 | 21 CFR Parts 210 and 211 (drug cGMP) |
| Key international framework | OECD Principles of GLP, applied via the Mutual Acceptance of Data (MAD) system | ICH Q7 (GMP for active pharmaceutical ingredients); EU GMP Annex 13/16 for investigational medicinal products |
| Stage of development | Preclinical / nonclinical — before human dosing | Manufacturing — spans preclinical through commercial production, including IMP for clinical trials |
| Unit of compliance | Per study — each nonclinical study either was or wasn't GLP-compliant | Per facility/quality system — ongoing compliance of the manufacturing site and process |
| Oversight role | Study Director and an independent Quality Assurance Unit (QAU) | Quality unit; in the EU, a Qualified Person (QP) who certifies batch release |
| Link to IND application | IND must state GLP-compliance status of each nonclinical safety study (21 CFR 312.23(a)(8)(iii)) | IND's CMC section must document phase-appropriate GMP manufacture of the investigational product |
| Phase-based flexibility | None — GLP either applies to a given study or it doesn't | Yes — 21 CFR 210.2(c) exempts most Phase 1 investigational drugs from the full scope of Part 211 |
| Consequence of noncompliance | Non-GLP pivotal toxicology data is a recognized basis for an FDA clinical hold or IND deficiency | CGMP inspection findings are documented on FDA Form 483; product can be rejected, recalled, or blocked from release |
| Relationship to GCP | Distinct — GCP (21 CFR 312 / ICH E6) governs the human trial itself, not the preceding nonclinical studies | Distinct — GCP governs trial conduct; GMP governs the product being administered |
Common questions
FAQ
Do I need GLP or GMP for a preclinical toxicology study?+
GLP. Preclinical/nonclinical safety and toxicology studies used to support an IND are governed by GLP (21 CFR Part 58), not GMP. GMP applies once you are manufacturing the drug substance or product itself.
Can the same facility be both GLP- and GMP-compliant?+
Yes, but they are separate compliance regimes with separate quality systems and oversight roles (Study Director/QAU for GLP vs. quality unit/QP for GMP). A facility running both nonclinical studies and manufacturing needs to maintain both programs distinctly — one doesn't substitute for the other.
Is GCP the same thing as GLP or GMP?+
No. GCP (Good Clinical Practice, ICH E6, implemented in the US via 21 CFR Part 312) governs conduct of the human clinical trial itself — informed consent, protocol adherence, monitoring. GLP governs the nonclinical studies that precede human dosing, and GMP governs manufacture of the product used in the trial. All three are commonly grouped as "GxP."
What is phase-appropriate GMP?+
Under 21 CFR 210.2(c), FDA exempts most Phase 1 investigational drugs from the full scope of 21 CFR Part 211, recognizing early-phase manufacturing controls can be less extensive than commercial manufacturing while still ensuring product quality and safety. GMP expectations increase through later trial phases toward approval. GLP has no equivalent phase-based exemption.
What happens if a pivotal toxicology study wasn't run under GLP?+
FDA expects pivotal nonclinical safety studies supporting an IND to be GLP-compliant. An IND must state the GLP-compliance status of each nonclinical safety study (21 CFR 312.23(a)(8)(iii)); non-GLP pivotal data is a recognized basis for a clinical hold or IND deficiency.
Going deeper
